Lantheus Holdings, Inc. current report, 04 March 2016

Full document

Lantheus Holdings, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Lantheus Holdings, Inc. on March 4, 2016. The report details significant changes to the composition of the Company's Board of Directors, including the retirement of a director and the appointment of two new directors.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements rather than financial performance.

Material Changes

  • Director Retirement: Dr. Patrick O'Neill tendered his retirement and resignation from the Board, effective March 4, 2016.
  • New Director Appointments: The Board appointed Dr. Derace Schaffer and Dr. Frederick Robertson effective March 4, 2016.
  • Board Size Increase: The Board size was increased from seven to eight directors to accommodate the new appointments.
  • Committee Reshuffling:
    • Dr. Schaffer was appointed to the Compensation Committee; Mr. Samuel Leno resigned from this committee.
    • Dr. Robertson was appointed to the Audit Committee; Mr. Sriram Venkataraman resigned from this committee.

Guidance, Outlook, and Compensation

The filing outlines the compensation structure for the new directors:

  • Cash Fees: $50,000 per calendar year (prorated for 2016) for Board service.
  • Committee Fees: Dr. Schaffer receives an additional $7,500 annually for the Compensation Committee; Dr. Robertson receives an additional $10,000 annually for the Audit Committee (both prorated for 2016).
  • Equity Grant: Each new director received 25,000 shares of restricted common stock, vesting in full on the first anniversary of the grant date.
  • Terms: Dr. Schaffer serves as a Class I Director (term expires at the 2016 annual meeting); Dr. Robertson serves as a Class II Director (term expires at the 2017 annual meeting).

Key Facts for Investor Verification

  • Confirm the effective date of Dr. O'Neill's departure and the immediate start date for Dr. Schaffer and Dr. Robertson.
  • Verify the total number of directors on the Board is now eight.
  • Review the vesting schedule for the 25,000 restricted stock shares granted to each new director.
  • Check the Company's press release (Exhibit 99.1) for additional context on the strategic rationale for these appointments.